Since January 2020, Chinese pharma companies have entered into four deals with siRNA players to develop innovative siRNA-based therapeutics in the background of its huge potential in the pharma industry as well to enhance their pipeline portfolios. This includes Hansoh Pharma’s strategic alliance with Silence Therapeutics which is claimed to be the third biggest siRNA-based strategic alliance globally in terms of the deal's overall value (16 million dollars) since Jan 2020.
Data and analytics company Global Data has predicted that the arrival of biosimilar therapies in the EU will continue to fall in the coming years following a wave pattern that has been occurring since 2006.
Die Biopharma-Industrie leidet unter einem Mangel an viralen Vektoren, einer Komponente, die für die Herstellung von Gentherapien und genmodifizierten Zelltherapien benötigt wird, berichtet Global Data. Auch bestimmte Covid-19-Impfstoffe benötigen virale Vektoren, insbesondere die von Astra Zeneca und Johnson & Johnson.
In 2020, the Food and Drug Administration (FDA) approved more biologic new molecular entities as compared to the previous years. In this background, the leading data and analytics company Global Data also found that the sponsors increased the outsourcing of these biologics’ active pharmaceutical ingredient (API) manufacturing.
As the world struggles to fight the pandemic, the demand and supply gaps for Covid-19 vaccines is widening. In this background, Global Data reveals that Chinese vaccines remain crucial for developing nations.
West China’s pharma manufacturing is lagging behind other regions in the country and requires international as well as domestic investment, states Global Data, a leading data and analytics company. However, human rights violations in China’s westernmost provinces have limited major foreign investments in the region.
Die ersten europäischen Werke produzieren bereits wieder oder stehen kurz davor. Doch bis wieder Normalität herrscht, werden Monate vergehen, warnt ein Analyst. Aufmerksamkeit erfordern nun vor allem die Endkunden und Sublieferanten.